GB0225579D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB0225579D0
GB0225579D0 GBGB0225579.2A GB0225579A GB0225579D0 GB 0225579 D0 GB0225579 D0 GB 0225579D0 GB 0225579 A GB0225579 A GB 0225579A GB 0225579 D0 GB0225579 D0 GB 0225579D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0225579.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0225579.2A priority Critical patent/GB0225579D0/en
Publication of GB0225579D0 publication Critical patent/GB0225579D0/en
Priority to JP2004549306A priority patent/JP2006508944A/ja
Priority to EP03769677A priority patent/EP1575943A1/en
Priority to US10/532,958 priority patent/US7173136B2/en
Priority to AU2003278369A priority patent/AU2003278369A1/en
Priority to PCT/GB2003/004661 priority patent/WO2004041811A1/en
Priority to US11/642,978 priority patent/US20070191346A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB0225579.2A 2002-11-02 2002-11-02 Chemical compounds Ceased GB0225579D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0225579.2A GB0225579D0 (en) 2002-11-02 2002-11-02 Chemical compounds
JP2004549306A JP2006508944A (ja) 2002-11-02 2003-10-28 ３−シアノ−キノリン誘導体
EP03769677A EP1575943A1 (en) 2002-11-02 2003-10-28 3-cyano-quinoline derivatives
US10/532,958 US7173136B2 (en) 2002-11-02 2003-10-28 3-Cyano-quinoline derivatives
AU2003278369A AU2003278369A1 (en) 2002-11-02 2003-10-28 3-cyano-quinoline derivatives
PCT/GB2003/004661 WO2004041811A1 (en) 2002-11-02 2003-10-28 3-cyano-quinoline derivatives
US11/642,978 US20070191346A1 (en) 2002-11-02 2006-12-21 3-Cyano-quinoline derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0225579.2A GB0225579D0 (en) 2002-11-02 2002-11-02 Chemical compounds

Publications (1)

Publication Number Publication Date
GB0225579D0 true GB0225579D0 (en) 2002-12-11

Family

ID=9947091

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0225579.2A Ceased GB0225579D0 (en) 2002-11-02 2002-11-02 Chemical compounds

Country Status (6)

Country Link
US (2) US7173136B2 (https=)
EP (1) EP1575943A1 (https=)
JP (1) JP2006508944A (https=)
AU (1) AU2003278369A1 (https=)
GB (1) GB0225579D0 (https=)
WO (1) WO2004041811A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215823D0 (en) * 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
GB0225579D0 (en) * 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
WO2008135886A2 (en) * 2007-05-02 2008-11-13 University Of Pretoria Quinoline derivatives for use in the inhibition of the growth of tumour cells
BRPI0819624B1 (pt) 2007-11-19 2017-12-12 Shell Internationale Research Maatschappij B.V. Method for determining a hydrotrating process using a metallic battery catalyst
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
ES2576061T3 (es) 2010-02-25 2016-07-05 Dana-Farber Cancer Institute, Inc. Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
WO2012166654A1 (en) * 2011-05-27 2012-12-06 The Regents Of The University Of California Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof
CA2754237A1 (en) 2011-05-27 2012-11-27 The Regents Of The University Of California Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
JP6740354B2 (ja) 2015-10-05 2020-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
RS65962B1 (sr) 2020-05-08 2024-10-31 Halia Therapeutics Inc Inhibitori nek7 kinaze
US20240158394A1 (en) 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE317376B (https=) * 1961-07-10 1969-11-17 Roussel Uclaf
FR2077455A1 (en) 1969-09-03 1971-10-29 Aries Robert 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials
US3936461A (en) * 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
FR2498187A1 (fr) * 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
IL89029A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
SG64322A1 (en) * 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2114727C (en) * 1991-08-02 1996-12-10 Mikel P. Moyer Quinoline derivatives as immunostimulants
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5656643A (en) * 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
EP0860433B1 (en) 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
AR007857A1 (es) * 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
WO1998013350A1 (en) 1996-09-25 1998-04-02 Zeneca Limited Qinoline derivatives inhibiting the effect of growth factors such as vegf
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
ATE255575T1 (de) 1998-09-29 2003-12-15 Wyeth Corp Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren
GB9904103D0 (en) * 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2002016352A1 (en) 2000-08-21 2002-02-28 Astrazeneca Ab Quinazoline derivatives
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
EP1337513A1 (en) 2000-11-02 2003-08-27 AstraZeneca AB 4-substituted quinolines as antitumor agents
JP4307843B2 (ja) 2001-04-19 2009-08-05 アストラゼネカ アクチボラグ キナゾリン誘導体
WO2003008409A1 (en) 2001-07-16 2003-01-30 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
AU2002347359A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives
AU2002365664A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives as antitumour agents
WO2003047585A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours
WO2003048159A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
AU2002365665A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Pharmaceutical compositions comprising benzofuranyl substituted 3-cyanoquinoline derivatives and their use for the treatment of solid tumours
GB0215823D0 (en) * 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
EP1528925B1 (en) 2002-07-09 2009-04-22 Astrazeneca AB Quinazoline derivatives for use in the treatment of cancer
GB0225579D0 (en) * 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
WO2004041811A1 (en) 2004-05-21
US7173136B2 (en) 2007-02-06
US20070191346A1 (en) 2007-08-16
US20050282856A1 (en) 2005-12-22
AU2003278369A1 (en) 2004-06-07
EP1575943A1 (en) 2005-09-21
JP2006508944A (ja) 2006-03-16

Similar Documents

Publication Publication Date Title
GB0209715D0 (en) Chemical compounds
GB0209467D0 (en) Chemical compounds
GB0205693D0 (en) Chemical compounds
GB0205165D0 (en) Chemical compounds
EG23485A (en) Chemical compounds
GB0203994D0 (en) Chemical compounds
AU2003287178A8 (en) Chemical compounds
GB0203020D0 (en) Chemical compounds
GB0205170D0 (en) Chemical compounds
GB0208224D0 (en) Chemical compounds
AU2003290661A8 (en) Chemical compounds
GB0205162D0 (en) Chemical compounds
GB0203022D0 (en) Chemical compounds
GB0207253D0 (en) Chemical compounds
GB0205690D0 (en) Chemical compounds
GB0225579D0 (en) Chemical compounds
AU2003284217A8 (en) Chemical compounds
GB0205166D0 (en) Chemical compounds
GB0208223D0 (en) Chemical compounds
GB0209789D0 (en) Chemical compounds
GB0207156D0 (en) Chemical compounds
GB0223357D0 (en) Chemical compounds
GB0209718D0 (en) Chemical compounds
GB0205956D0 (en) Chemical compounds
GB0209716D0 (en) Chemical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)